Gut-derived incretin hormones and new therapeutic approaches.
Bloomgarden
Zachary T
ZT
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology*; D000077270:Exenatide; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism*; D005934:Glucagon / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use; D011498:Protein Precursors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use
D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D014688:Venoms; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide